Combined Enalapril and Felodipine Extended Release (ER) for Systemic Hypertension

This multicenter, placebo-controlled, double-blind trial of factorial design evaluated the safety and efficacy of combination treatment with the angiotensin-converting enzyme inhibitor, enalapril, and the vascular selective calcium antagonist felodipine extended release (ER) in patients with essenti...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of cardiology 1997-02, Vol.79 (4), p.431-435
Main Authors: Gradman, Alan H., Cutler, Neal R., Davis, Pamela J., Robbins, John A., Weiss, Robert J., Wood, Barry C.
Format: Article
Language:English
Subjects:
Antihypertensive agents
Biological and medical sciences
Cardiovascular system
Drug therapy
Hypertension
Medical sciences
Pharmacology. Drug treatments
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This multicenter, placebo-controlled, double-blind trial of factorial design evaluated the safety and efficacy of combination treatment with the angiotensin-converting enzyme inhibitor, enalapril, and the vascular selective calcium antagonist felodipine extended release (ER) in patients with essential hypertension. After a 4-week, single-blind placebo baseline period, 707 patients with sitting diastolic blood pressures (BPs) in the range of 95 to 115 mm Hg received placebo, enalapril (5 or 20 mg), felodipine ER (2.5, 5, or 10 mg), or their combinations for an 8-week double-blind treatment period. All doses of enalapril and felodipine ER had a statistically significant (p
ISSN:0002-9149
1879-1913
DOI:10.1016/S0002-9149(96)00781-3